Kapitalo Investimentos Ltda Takes $241,000 Position in Puma Biotechnology, Inc. $PBYI

Key Points

• Kapitalo Investimentos Ltda has acquired a new position in Puma Biotechnology, Inc., purchasing 70,269 shares valued at approximately $241,000.
• CEO Alan H. Auerbach and Director Alessandra Cesano have both sold shares of the company, with total insider sales amounting to 81,989 shares worth $285,351 in the last quarter.
• Analysts have upgraded Puma Biotechnology from a "buy" to a "strong-buy" rating and set an average target price of $7.00 for the stock.

Kapitalo Investimentos Ltda bought a new position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm bought 70,269 shares of the biopharmaceutical company's stock, valued at approximately $241,000. Kapitalo Investimentos Ltda owned approximately 0.14% of Puma Biotechnology as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. ProShare Advisors LLC acquired a new position in Puma Biotechnology in the fourth quarter valued at approximately $36,000. Causeway Capital Management LLC purchased a new position in shares of Puma Biotechnology during the 1st quarter worth $42,000. PFG Investments LLC acquired a new position in shares of Puma Biotechnology in the 1st quarter worth approximately $59,000. Hsbc Holdings PLC purchased a new stake in shares of Puma Biotechnology in the 1st quarter valued at $61,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Puma Biotechnology by 104,365.0% in the 1st quarter. Russell Investments Group Ltd. now owns 20,893 shares of the biopharmaceutical company's stock valued at $62,000 after buying an additional 20,873 shares during the period. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Puma Biotechnology

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 25,592 shares of the business's stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $3.53, for a total transaction of $90,339.76. Following the transaction, the chief executive officer owned 7,202,481 shares in the company, valued at approximately $25,424,757.93. The trade was a 0.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Alessandra Cesano sold 27,000 shares of the business's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $3.37, for a total transaction of $90,990.00. Following the sale, the director owned 41,850 shares in the company, valued at $141,034.50. The trade was a 39.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,989 shares of company stock worth $285,351 in the last quarter. 23.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $7.00.

Puma Biotechnology Stock Down 2.2%

Shares of Puma Biotechnology stock opened at $4.42 on Monday. The company has a market cap of $222.64 million, a P/E ratio of 4.51 and a beta of 1.37. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.62 and a current ratio of 1.73. Puma Biotechnology, Inc. has a one year low of $2.32 and a one year high of $6.07. The firm has a fifty day moving average of $4.29 and a two-hundred day moving average of $3.61.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.